Brief: Arix Bioscience Artios Doses First Patient In Phase 1/2A Study Of POlθ Inhibitor ART4215
28/09/2021 08:51
Sept 28 (Reuters) - Arix Bioscience PLC ARIX.L :
* REG-ARIX BIOSCIENCE PLC ARTIOS DOSES FIRST PATIENT IN
PHASE 1/2A
STUDY OF POLΘ INHIBITOR ART4215
Source text for Eikon: ID:nEQ7w8WKKa
Further company coverage: ARIX.L
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arix Bioscience
See all newsBrief: Arix Bioscience Says Sale Of Harpoon Is Expected To Deliver Net Proceeds Of About $18.9 Mln
Brief: Arix Bioscience Total NAV Of £228.5 MLN As At 31 October 2023
Brief: RTW Biotech To Acquire Arix Bioscience's Assets
RTW Biotech to acquire Arix Bioscience's assets
Brief: Arix Bioscience Says Board Exploring Range Of Strategic Options For Co